To Biao Bayer!

On July 9, Sihuan Pharmaceutical issued an announcement stating that the Moxifloxacin Hydrochloride and Sodium Chloride Injection developed by the group obtained the "Drug Registration Certificate" issued by the State Food and Drug Administration

Data show that moxifloxacin hydrochloride is a fourth-generation quinolone antibacterial drug, which has broad-spectrum antibacterial activity against gram-positive bacteria, gram-negative bacteria, anaerobic bacteria, acid-fast bacteria and atypical microorganisms such as mycoplasma, chlamydia and legionella

Sales of terminal moxifloxacin hydrochloride and sodium chloride injection in Chinese public medical institutions in recent years (unit: 100 million yuan)

Source: Terminal competition landscape of China's public medical institutions

Meinenet data shows that in recent years, the sales of terminal moxifloxacin hydrochloride and sodium chloride injection in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown steadily, and will create a new record in 2020.

Source: Meinenet MED2.

In terms of consistency evaluation, Moxifloxacin Hydrochloride and Sodium Chloride Injection has been reviewed by 9 companies, of which 5 companies including Yangzijiang Pharmaceutical Group, Sichuan Kelun Pharmaceutical and Jiangsu Zhengda Fenghai Pharmaceutical have been approved for supplementary applications.

At present, 10 companies of Moxifloxacin Hydrochloride and Sodium Chloride Injection have submitted listing applications for review and approval.

Sihuan Pharmaceutical stated that the anti-infective field is the key area of ​​the group's layout.

Source: Listed company announcements, Mi Nei.